--- title: "Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of \"Moderate Buy\" from Brokerages" type: "News" locale: "en" url: "https://longbridge.com/en/news/295285840.md" description: "Spyglass Pharma (NASDAQ:SGP) holds a consensus 'Moderate Buy' rating from seven analysts, with five buy, one hold, and one sell ratings. Weiss Ratings recently added a 'sell (e)' rating. The average 12-month price target is $45.00. Shares rose to $25.31 on Friday. The company missed Q2 EPS estimates, reporting ($0.59) vs. ($0.48) expected. Institutional investors including Affinity Asset Advisors and First Light Asset Management increased stakes in recent quarters." datetime: "2026-08-08T00:14:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295285840.md) - [en](https://longbridge.com/en/news/295285840.md) - [zh-HK](https://longbridge.com/zh-HK/news/295285840.md) generator: "portal-rs" --- # Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $45.00. Separately, Weiss Ratings assumed coverage on shares of Spyglass Pharma in a report on Thursday. They set a "sell (e)" rating on the stock. Get **Spyglass Pharma** alerts: **Check Out Our Latest Analysis on SGP** ## Spyglass Pharma Stock Performance Shares of SGP stock traded up $0.56 during mid-day trading on Friday, reaching $25.31. 72,029 shares of the stock traded hands, compared to its average volume of 109,251. The business has a fifty day moving average price of $20.25. Spyglass Pharma has a 1-year low of $17.06 and a 1-year high of $32.44. The stock has a market capitalization of $846.11 million and a P/E ratio of -3.95. Spyglass Pharma (NASDAQ:SGP - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.11). Equities research analysts expect that Spyglass Pharma will post -2 EPS for the current fiscal year. ## Institutional Inflows and Outflows Hedge funds have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC acquired a new position in shares of Spyglass Pharma in the 1st quarter worth approximately $6,478,000. First Light Asset Management LLC acquired a new stake in shares of Spyglass Pharma during the first quarter worth $9,716,000. Monashee Investment Management LLC bought a new position in Spyglass Pharma during the first quarter worth $2,461,000. Bank of New York Mellon Corp bought a new position in Spyglass Pharma during the second quarter worth $533,000. Finally, Bank of America Corp DE acquired a new position in Spyglass Pharma in the first quarter valued at $726,000. ## About Spyglass Pharma (Get Free Report) We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). ## Featured Stories - Five stocks we like better than Spyglass Pharma - Datadog’s Drop Says More About Expectations Than Earnings - D-Wave's Quantum Breakthrough Couldn't Save QBTS From a Sell-Off - Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus - Solventum Nears Inflection Point As It Begins to Unlock Value *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Spyglass Pharma Right Now? Before you consider Spyglass Pharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list. While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SGP.US](https://longbridge.com/en/quote/SGP.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [DDOG.US](https://longbridge.com/en/quote/DDOG.US.md) - [QBTS.US](https://longbridge.com/en/quote/QBTS.US.md) - [NET.US](https://longbridge.com/en/quote/NET.US.md) - [SOLV.US](https://longbridge.com/en/quote/SOLV.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) - [QBTS+.US](https://longbridge.com/en/quote/QBTS+.US.md) ## Related News & Research - [Spyglass Pharma posts corporate deck on long-acting intraocular drug delivery for glaucoma, ocular hypertension patients](https://longbridge.com/en/news/295701214.md) - [Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.6% - Here's What Happened](https://longbridge.com/en/news/282580053.md) - [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md) - [Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RNA Stock News](https://longbridge.com/en/news/296542298.md) - [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**